Eric Berger. Show Affiliations »
Abstract
Mesh： See more » AuthorshipClinical Trials as Topic/economicsClinical Trials as Topic/ethicsClinical Trials as Topic/legislation & jurisprudenceClinical Trials as Topic/standardsConflict of Interest/economicsCyclooxygenase 2 Inhibitors/adverse effectsDisclosure/standardsDrug Industry/economicsDrug Industry/legislation & jurisprudenceEditorial PoliciesGovernment RegulationLactones/adverse effectsPeriodicals as Topic/standardsPublication Bias/statistics & numerical dataResearch Support as Topic/ethicsResearch Support as Topic/legislation & jurisprudenceResearch Support as Topic/trendsSulfones/adverse effectsUnited States
Substances： See more » Cyclooxygenase 2 InhibitorsLactonesSulfonesrofecoxib
Year: 2008 PMID： 18672488 DOI： 10.1016/j.annemergmed.2008.06.009
Source DB: PubMed Journal: Ann Emerg Med ISSN： 0196-0644 Impact factor: 5.721